NeoPharm Co. Ltd.
Korea ExchangeTotal Valuation
NeoPharm Co. Ltd. carries a market capitalization of 179.25B, placing it among publicly traded companies globally. Its enterprise value stands at -145.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 179.25B |
| Enterprise Value | -145.94B |
Share Statistics
NeoPharm Co. Ltd. currently has 15.64M shares outstanding.
| Shares Outstanding | 15.64M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
NeoPharm Co. Ltd. maintains a current ratio of 5.75, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.86, indicating moderate leverage, while an interest coverage ratio of 629.28 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.75 |
| Quick Ratio | 4.60 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 0.06 |
| Interest Coverage | 629.28 |
Financial Efficiency
NeoPharm Co. Ltd. posts a return on equity of 20.22 and a return on invested capital of 13.40.
| Return on Equity (ROE) | 20.22 |
| Return on Assets (ROA) | 13.75 |
| Return on Invested Capital (ROIC) | 13.40 |
| Return on Capital Employed (ROCE) | 20.10 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.15 |
Taxes
Over the trailing twelve months, NeoPharm Co. Ltd. has paid 5.06B in income taxes, reflecting an effective tax rate of 14.72.
| Income Tax | 5.06B |
| Effective Tax Rate | 14.72 |
Stock Price Statistics
NeoPharm Co. Ltd.'s stock has declined approximately -7.95181% over the past 52 weeks. The 50-day moving average sits at 11,655.00, while the 200-day moving average is 12,563.43.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.95181% |
| 50-Day Moving Average | 11,655.00 |
| 200-Day Moving Average | 12,563.43 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, NeoPharm Co. Ltd. generated 136.80B in revenue and converted that into 29.31B in net income, yielding earnings per share of 1,873.49. EBITDA reached 29.70B, while operating income came in at 29.70B.
| Revenue | 136.80B |
| Gross Profit | 89.81B |
| Operating Income | 29.70B |
| Pretax Income | 34.37B |
| Net Income | 29.31B |
| EBITDA | 29.70B |
| EBIT | 29.70B |
| Earnings Per Share (EPS) | 1,873.49 |
Balance Sheet
NeoPharm Co. Ltd. holds 147.59B in cash and equivalents against 1.65B in total debt, resulting in a net debt position of -31.92B. Total book value stands at 153.56B, with working capital of 152.51B providing operational flexibility.
| Cash & Cash Equivalents | 147.59B |
| Total Debt | 1.65B |
| Net Debt | -31.92B |
| Equity (Book Value) | 153.56B |
| Book Value Per Share | 9,815.58 |
| Working Capital | 152.51B |
Cash Flow
NeoPharm Co. Ltd. produced 24.68B in operating cash flow over the past twelve months. After subtracting -1.36B in capital expenditures, free cash flow totaled 23.32B - equivalent to 1,490.36 per share.
| Operating Cash Flow | 24.68B |
| Capital Expenditures | -1.36B |
| Free Cash Flow | 23.32B |
| FCF Per Share | 1,490.36 |
Margins
NeoPharm Co. Ltd. operates with a gross margin of 65.65, reflecting its pricing power and cost economics. The operating margin of 21.71 and net profit margin of 21.43 provide insight into operational efficiency.
| Gross Margin | 65.65 |
| Operating Margin | 21.71 |
| Pretax Margin | 25.12 |
| Profit Margin | 21.43 |
| EBITDA Margin | 21.71 |
Stock Splits
NeoPharm Co. Ltd.'s most recent stock split took place on October 30, 2024 with a 1:2 split ratio.
| Last Split Date | 10/30/2024 |
| Split Ratio | 1:2 |
Scores
NeoPharm Co. Ltd. posts an Altman Z-Score of 2.78, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.78 |